1-20 of 73
William Plunkett
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Clinical Trials & Observations Brief Report
Philip A. Thompson, Alexandre Bazinet, William G. Wierda, Constantine S. Tam, Susan M. O’Brien, Satabdi Saha, Christine B. Peterson, William Plunkett, Michael J. Keating
Journal: Blood
Blood (2023) 142 (21): 1784–1788.
https://doi.org/10.1182/blood.2023020158
Published: 2023
Includes: Supplemental data
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Nitin Jain, Philip Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati, Koichi Takahashi, Mahesh Swaminathan, Zeev Estrov, Gautam Borthakur, Prithviraj Bose, Tapan M. Kadia, Naveen Pemmaraju, Koji Sasaki, Divyam Bansal, Marina Y. Konopleva, Elias Jabbour, Naveen Garg, Xuemei Wang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Wei Wang, Sa A. Wang, Jeffrey L. Jorgensen, Wanda Lopez, Ana Ayala, William Plunkett, Varsha Gandhi, Hagop M. Kantarjian, Susan M. O'Brien, Michael J. Keating, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 3267.
https://doi.org/10.1182/blood-2023-188084
Published: 2023
Journal Articles

Investigation into Intraclonal Heterogeneity of CXCR4 Dim CD5 Bright Chronic Lymphocytic Leukemia Cells Identifies Distinct Activation Signatures

Anita Ng, Andrew Shih, Martina Cardillo, Kristin Lynn Sticco, Houman Khalili, Lita Crichton, William Plunkett, Varsha Gandhi, Nicholas Chiorazzi
Journal: Blood
Blood (2023) 142 (Supplement 1): 3259.
https://doi.org/10.1182/blood-2023-187957
Published: 2023
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Mahesh Swaminathan, Koichi Takahashi, Zeev Estrov, Marina Y. Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado Valero, Musa Yilmaz, Prithviraj Bose, Maro Ohanian, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A. Wang, Sameh Nassar, Naveen Garg, Hyunsoo Hwang, Xuemei Wang, Nichole Cruz, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 4635.
https://doi.org/10.1182/blood-2023-189711
Published: 2023
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jayastu Senapati, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Marina Konopleva, Koji Sasaki, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Yesid Alvarado, Musa Yilmaz, Prithviraj Bose, Maro Ohanian, Rashmi Kanagal-Shamanna, Keyur Patel, Jeffrey L. Jorgensen, Sa A Wang, Sameh Nassar, Naveen Garg, Hyunsoo Hwang, Xuemei Wang, Nichole Cruz, Ana Ayala, William Plunkett, Hagop Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 234–237.
https://doi.org/10.1182/blood-2022-170850
Published: 2022
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results

Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev E. Estrov, Koji Sasaki, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yilmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias J. Jabbour, Rashmi Kanagal-Shamanna, Keyur Patel, Wei Wang, Jeffrey L. Jorgensen, Sa A Wang, Naveen Garg, Xuemei Wang, Chongjuan Wei, Nichole Cruz, Ana Ayala, William Plunkett, Hagop Kantarjian, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2021) 138 (Supplement 1): 3720.
https://doi.org/10.1182/blood-2021-154454
Published: 2021
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Koji Sasaki, MD, Nathan H Fowler, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wei Wang, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Chongjuan Wei, PhD, Nichole Cruz, RN, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-142014
Published: 2020
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, MD, Michael J Keating, MBBS, Philip A. Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam M. Borthakur, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Marina Y Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MDMSc, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 34.
https://doi.org/10.1182/blood-2019-131847
Published: 2019
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Koji Sasaki, MD, Naveen Garg, MD, Xuemei Wang, MS, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Wanda Lopez, RN, Ana Ayala, RN, William Plunkett, PhD, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 357.
https://doi.org/10.1182/blood-2019-131939
Published: 2019
Journal Articles

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Koichi Takahashi, MD, Prithviraj Bose, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Naval G. Daver, MD, Marina Y Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSc, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 359.
https://doi.org/10.1182/blood-2019-131732
Published: 2019
Journal Articles

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, MD PhD, Seung Tae Lee, MD PhD, Rong Chen, PhD, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD, William Plunkett, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1761.
https://doi.org/10.1182/blood-2019-128956
Published: 2019
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Zeev E. Estrov, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Naveen Garg, MD, Xuemei Wang, MS, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wanda Lopez, RN, Ana Ayala, RN, William Plunkett, PhD, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 695.
https://doi.org/10.1182/blood-2018-185
Published: 2018
Journal Articles

Using HSP90 Inhibitors to Target DNA Repair Proteins in AML

Janani Ravikrishnan, BS, Tzung-Huei Lai, PhD, Shaneice Renee Mitchell, BS, Pei-Jung Wu, BS, Shelley Orwick, BS, Chaomei Liu, PhD, Jennifer A. Woyach, MD, Alice S. Mims, MD, William Plunkett, PhD, Vinay K Puduvalli, MD MBBS, John C. Byrd, MD, Rosa Lapalombella, PhD, Deepa Sampath, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5144.
https://doi.org/10.1182/blood-2018-99-116485
Published: 2018
Journal Articles

Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, MD, Michael J Keating, MBBS, Philip A. Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MDMSc, Prithviraj Bose, MD, Maro N. Ohanian, DO, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 696.
https://doi.org/10.1182/blood-2018-186
Published: 2018
Journal Articles

Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial

Nitin Jain, MD, Philip A Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD, Prithviraj Bose, MD, Zeev Estrov, MD, Elias J. Jabbour, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Tapan Kadia, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MDMSc, Maro Ohanian, DO, Jorge E. Cortes, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Naveen Garg, MD, Xuemei Wang, Nina Fru, RN, Nichole Cruz, RN, Varsha Gandhi, PhD, William Plunkett, PhD, Hagop M. Kantarjian, MD, Michael J. Keating, MD, William G Wierda, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 429.
https://doi.org/10.1182/blood.V130.Suppl_1.429.429
Published: 2017
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Nitin Jain, MD, Philip A Thompson, MBBS, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Prithviraj Bose, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Naveen Garg, MD, Xuemei Wang, Varsha Gandhi, PhD, William Plunkett, PhD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wanda Lopez, RN, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael J Keating, William G Wierda, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 495.
https://doi.org/10.1182/blood.V130.Suppl_1.495.495
Published: 2017
Journal Articles

Targeting BTK through microRNA in chronic lymphocytic leukemia

Arianna Bottoni, Lara Rizzotto, Tzung-Huei Lai, Chaomei Liu, Lisa L. Smith, Rose Mantel, Sean Reiff, Dalia El-Gamal, Karilyn Larkin, Amy J. Johnson, Rosa Lapalombella, Amy Lehman, William Plunkett, John C. Byrd, James S. Blachly, Jennifer A. Woyach, Deepa Sampath
Journal: Blood
Blood (2016) 128 (26): 3101–3112.
https://doi.org/10.1182/blood-2016-07-727750
Published: 2016
Includes: Supplemental data
Journal Articles

Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study

Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Naval G. Daver, MD, Gautam Borthakur, MD, Nitin Jain, MD, Jane Waukau, RN, BSN, Monica Kwari, RN, BSN, Barry Douglas Anderson, MD PhD, Kenzo Iizuka, Cheng Jin, MD PhD, Chun Zhang, MD, Farhad Ravandi, MD, William Plunkett, PhD
Journal: Blood
Blood (2016) 128 (22): 2822.
https://doi.org/10.1182/blood.V128.22.2822.2822
Published: 2016
Journal Articles

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV- mutated chronic lymphocytic leukemia

Clinical Trials & Observations
Philip A. Thompson, Constantine S. Tam, Susan M. O’Brien, William G. Wierda, Francesco Stingo, William Plunkett, Susan C. Smith, Hagop M. Kantarjian, Emil J. Freireich, Michael J. Keating
Journal: Blood
Blood (2016) 127 (3): 303–309.
https://doi.org/10.1182/blood-2015-09-667675
Published: 2016
Includes: Supplemental data
Journal Articles

Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia

Hagop Kantarjian, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, Courtney DiNardo, MD, Naval Daver, MD, Gautam Borthakur, MD, Nitin Jain, MD, Jane Waukau, RN, BSN, Monica Kwari, RN, BSN, Barry Douglas Anderson, MD PhD, Kenzo Iizuka, Cheng Jin, MD PhD, William Plunkett, PhD
Journal: Blood
Blood (2015) 126 (23): 3804.
https://doi.org/10.1182/blood.V126.23.3804.3804
Published: 2015